Cryo Cell International Inc: Form 10-Q for the period ended May 31, 2013
Filed with the SEC on Jul 15, 2013 and accepted by EDGAR at Jul 15, 2013, 21:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-03-01 to 2013-05-31 | $4.9m | us-gaap:Revenues |
| Revenue | 6 months2012-12-01 to 2013-05-31 | $9.5m | us-gaap:Revenues |
| Cost of revenue | 3 months2013-03-01 to 2013-05-31 | $1.4m | us-gaap:CostOfServices |
| Cost of revenue | 6 months2012-12-01 to 2013-05-31 | $2.7m | us-gaap:CostOfServices |
| Research and development | 3 months2013-03-01 to 2013-05-31 | $7.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2012-12-01 to 2013-05-31 | $18.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2013-03-01 to 2013-05-31 | $3.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2012-12-01 to 2013-05-31 | $5.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2013-03-01 to 2013-05-31 | $88.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2012-12-01 to 2013-05-31 | $651.9k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2013-03-01 to 2013-05-31 | $262.2k | us-gaap:InterestExpense |
| Interest expense | 6 months2012-12-01 to 2013-05-31 | $512.7k | us-gaap:InterestExpense |
| Income tax | 3 months2013-03-01 to 2013-05-31 | $42.8k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2012-12-01 to 2013-05-31 | $85.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-03-01 to 2013-05-31 | −$243.7k | us-gaap:NetIncomeLoss |
| Net income | 6 months2012-12-01 to 2013-05-31 | $348 | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-03-01 to 2013-05-31 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2012-12-01 to 2013-05-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-03-01 to 2013-05-31 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2012-12-01 to 2013-05-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2013-03-01 to 2013-05-31 | 10,946,743 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2012-12-01 to 2013-05-31 | 11,082,564 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2012-12-01 to 2013-05-31 | $1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2012-12-01 to 2013-05-31 | $230.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2012-12-01 to 2013-05-31 | $668.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2013-05-31 | $2.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-05-31 | $9.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-05-31 | $11.9m | us-gaap:Assets |
| Current liabilities | At period end2013-05-31 | $10.7m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2013-05-31 | $2.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2013-05-31 | −$9.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-13-290824. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.